Dividend Kings—companies that have increased their dividends for at least 50 consecutive years—represent one of the most exclusive clubs in investing. The need to enter is a proof of financial behavior. A company must maintain profit growth undisturbed by recessions, market crashes, interest rate cycles, and industry disruptions.
Less than 60 US companies holding the title as of 2026. But holding the title alone does not make the stock worth owning. Some Kings are low-growth businesses that are supported by increased yields mainly because the share price has fallen. The three below are different. Each has a pedigree and the basics to support it.
Healthcare Dividend King With Powerful Post-Spinoff Business
Johnson & Johnson NYSE: JNJ it has raised its dividends for 64 consecutive years—a record dating back to the early 1960s—and has survived the oil shock, dot-com crash, financial crisis, and global pandemic. But what makes JNJ particularly compelling today is the transformation of its business.
Johnson & Johnson Today
Johnson & Johnson
- 52 week interval
- $149.04
▼
$251.71
- Dividend Yield
- 2.38%
- The P/E ratio
- 26.03
- Target Value
- $253.04
In 2023, J&J completed the spinoff of its consumer products division into a separate, publicly traded company called Kenvue. NYSE: KVUEwith products like Tylenol, Band-Aid, and Listerine. The move was controversial at the time, but the strategy has worked. The remaining J&J is now a pure-play pharmaceutical and MedTech company.
That means the company now has a lucrative business with a pipeline that management has backed with aggressive R&D investments. A dying consumer segment, while stable, was holding back a lot. In addition, investors gain direct exposure to J&J’s oncology, immunology, and neuroscience pipelines. The stock is up nearly 50% over the past year. This reflects the market’s recent recognition that the business is fundamentally better off after a spinoff.
The dividend yield sits at around 2.3%, low by Dividend King standards, but paired with a balance sheet that is one of only a handful in the S&P 500 to carry a AAA credit rating. For investors looking for income growth based on real business quality rather than financial engineering, J&J is a standout.
Consumer Staples Giant Built for Long-Term Earnings Growth
PepsiCo NASDAQ: PEP it’s one of those companies that stays under bull markets and quietly thrives over full market cycles. It has increased its dividends for 54 consecutive years and owns the most recognized brand portfolio in the world, including: Pepsi, Gatorade, Lay’s, Doritos, Quaker, and Tropicana. More than 20 brands generate more than $1 billion in sales each year.
PepsiCo Today
As of 05/29/2026 04:00 PM Eastern
- 52 week interval
- $127.60
▼
$171.48
- Dividend Yield
- 3.95%
- The P/E ratio
- 22.64
- Target Value
- $170.11
An underappreciated part of the PepsiCo story is how that diversity works as a hedge. If the volume of the drink is soft, the volume of the snack is tight. As North American consumers tighten their spending, international growth slows.
The company has demonstrated the ability to raise prices without hurting volume, the kind of real pricing power that not all packaged food companies can claim. Living income growth of 1%–3% per quarter may not sound exciting, but it remains remarkably consistent across economies while consolidating significantly over the past decade.
it paid a dividend of 3.9% compared to yesterday, with an annual yield of 4%. That extends the company’s decade-long record of delivering revenue growth that exceeds revenue.
PepsiCo is not a stock that will make a portfolio double in two years. But it will quietly build wealth over a decade with reinvested dividends, earnings growth, and the kind of resilience that makes it a reliable ballast when growth stocks are remade. For near-term or retirement investors, or for anyone looking for income that truly grows in purchasing power, PEP is part of the conversation.
The Overlooked Medical Technology Dividend King Company
Becton, Dickinson and Co. NYSE: BDX is Dividend King which is not a household name for many income investors. The company manufactures needles, syringes, infusion systems, diagnostic equipment, and lab automation equipment that are constantly being purchased by hospitals and clinics, regardless of the economic climate.
Becton, Dickinson and Company Today
Becton, Dickinson and Company
- 52 week interval
- $127.59
▼
$187.35
- Dividend Yield
- 2.85%
- The P/E ratio
- 37.25
- Target Value
- $183.64
That defensive income profile creates a solid foundation, but BDX also has a credible growth story stacked up. The company is investing heavily in its diagnostics and pharmaceutical management businesses, both of which benefit from the country’s practices in hospital efficiency and infection control. Management is targeting low-single-digit revenue growth in fiscal 2026 and earnings per share of $14.75 to $15.05 in the mid-range, representing modest but steady growth of 3.5%.
With a 2.8% dividend yield that currently sits above the S&P 500 average, 53 years of uninterrupted dividend growth, and a recession-proof business model, BDX offers something extremely rare: income that comes with no inherent business risk. It’s the kind of holding that long-term investors look back on ten years later and wish they’d bought more at prices like these.
Before you consider Johnson & Johnson, you’ll want to hear this.
MarketBeat tracks Wall Street’s top and most effective research analysts and the stocks they recommend to their clients every day. MarketBeat identified five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Johnson & Johnson wasn’t on the list.
Although Johnson & Johnson currently has an Average Buy rating among analysts, top analysts believe these five stocks are the best.
View Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help first-time investors build long-term wealth without knowing options, technology, or other advanced strategies.
Get This Free Report
